UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041936
Receipt number R000047853
Scientific Title Clinical evaluation study on the safety of new liquid enteral nutrition formula.
Date of disclosure of the study information 2020/10/01
Last modified on 2021/09/29 15:56:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical evaluation study on the safety of new liquid enteral nutrition formula.

Acronym

Clinical evaluation study of new liquid enteral nutrition formula.

Scientific Title

Clinical evaluation study on the safety of new liquid enteral nutrition formula.

Scientific Title:Acronym

Clinical evaluation study of new liquid enteral nutrition formula.

Region

Japan


Condition

Condition

Patients requiring the nutritional management using tube feeding.

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

For patients who received the new liquid enteral nutrition formula, clinical symptoms after administration will be examined and clinical evaluation will be performed.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Nutrition management completion rate

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Administer the new liquid enteral nutrition formula for 7 to 28 days.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with nasal tube feeding and gastrostomy tube feeding indication.
2) Patients in hospital.
3) Patients with the consent of the patient or his / her substitute.
4) Patients over 20 years old at the time of consent.
5) Patients with the tip of a tube feeding catheter placed in the stomach.

Key exclusion criteria

1) Patients who may have food allergies or allergic reactions to the products used in this study.
2) Patients with severe diarrhea within a week before the start of administration of the new liquid enteral nutrition formula.
3) Patients with gastroesophageal reflux.
4) Patients with ileus.
5) Patients who have difficulty in participating in this study due to complications such as liver disorder, renal disorder, and heart disease.
6) Patients who are pregnant and breastfeeding, or who may be pregnant.
7) Patients who judged not to be appropriate for study by the medical attendant.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Hideharu
Middle name
Last name Yamanaka

Organization

Wakakusa Daiichi Hospital

Division name

Surgery

Zip code

579-8056

Address

1-6 Wakakusa-cho, Higashi-Osaka City, Osaka, Japan

TEL

072-988-1409

Email

yamanakah@wakakoukai.or.jp


Public contact

Name of contact person

1st name Hideharu
Middle name
Last name Yamanaka

Organization

Wakakusa Daiichi Hospital

Division name

Surgery

Zip code

579-8056

Address

1-6 Wakakusa-cho, Higashi-Osaka City, Osaka, Japan

TEL

072-988-1409

Homepage URL


Email

yamanakah@wakakoukai.or.jp


Sponsor or person

Institute

Wakakusa Daiichi Hospital

Institute

Department

Personal name



Funding Source

Organization

NUTRI Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Wakakusa Daiichi Hospital

Address

1-6 Wakakusa-cho, Higashi-Osaka City, Osaka, Japan

Tel

072-988-1409

Email

wakakusa@wakakoukai.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 09 Month 24 Day

Date of IRB

2020 Year 09 Month 14 Day

Anticipated trial start date

2020 Year 10 Month 01 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 09 Month 29 Day

Last modified on

2021 Year 09 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047853


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name